- Email: [email protected]
HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
161 JACC March 21, 2017 Volume 69, Issue 11
Acute and Stable Ischemic Heart Disease HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Poster Contributions Poster Hall, Hall C Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m. Session Title: Advances in Lipid Management Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy Presentation Number: 1203-315 Authors: Ibadete Bytyci, Gani Bajraktari, Deepak L. Bhatt, Charity J. Morgan, Ali Ahmed, Wilbert S. Aronow, Maciej Banach, on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group, Clinic of Cardiology, Prishtina, Albania, Medical University of Lodz, Lodz, Poland
Background: Hydrophilic statins may be more beneficial than lipophilic statins in patients with acute ischemia undergoing percutaneous coronary intervention (PCI). In the current meta-analysis we examined the effect of lipophilic in comparison with hydrophilic statins in patients with acute coronary syndrome (ACS) and undergoing PCI. Methods: We systematically searched selected electronic databases up to July 2016 in order to identify randomized controlled trials (RCTs) which compared clinical outcomes of hydrophilic vs. lipophilic statins in ACS patients. Primary outcomes were major adverse cardiac events (MACE), myocardial infarction (MI), cardiac revascularization, stroke, cardiovascular (CV) hospitalization, cardiovascular (CV) and all-cause of mortality.
Results: A total of 8708 patients from 8 RCTs had been randomized to receive lipophilic (n=4277) or hydrophilic statins (n=4431), with mean follow-up 12.4 months, and were included to the meta-analysis. In comparison to hydrophilic statins, the lipophilic statins showed comparable risk reduction of MACE (relative risk [RR]=1.05, 95% CI, 0.88 to 1.25, p=0.591; Figure). Similar effects were observed on MI and CV death (Figure) and other outcomes.
Conclusions: We found no evidence of differential effect on MACE or other outcomes between lipophilic and hydrophilic statins in patients with ACS undergoing PCI.
Acute and Stable Ischemic Heart Disease HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Poster Contributions Poster Hall, Hall C Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m. Session Title: Advances in Lipid Management Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy Presentation Number: 1203-315 Authors: Ibadete Bytyci, Gani Bajraktari, Deepak L. Bhatt, Charity J. Morgan, Ali Ahmed, Wilbert S. Aronow, Maciej Banach, on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group, Clinic of Cardiology, Prishtina, Albania, Medical University of Lodz, Lodz, Poland
Background: Hydrophilic statins may be more beneficial than lipophilic statins in patients with acute ischemia undergoing percutaneous coronary intervention (PCI). In the current meta-analysis we examined the effect of lipophilic in comparison with hydrophilic statins in patients with acute coronary syndrome (ACS) and undergoing PCI. Methods: We systematically searched selected electronic databases up to July 2016 in order to identify randomized controlled trials (RCTs) which compared clinical outcomes of hydrophilic vs. lipophilic statins in ACS patients. Primary outcomes were major adverse cardiac events (MACE), myocardial infarction (MI), cardiac revascularization, stroke, cardiovascular (CV) hospitalization, cardiovascular (CV) and all-cause of mortality.
Results: A total of 8708 patients from 8 RCTs had been randomized to receive lipophilic (n=4277) or hydrophilic statins (n=4431), with mean follow-up 12.4 months, and were included to the meta-analysis. In comparison to hydrophilic statins, the lipophilic statins showed comparable risk reduction of MACE (relative risk [RR]=1.05, 95% CI, 0.88 to 1.25, p=0.591; Figure). Similar effects were observed on MI and CV death (Figure) and other outcomes.
Conclusions: We found no evidence of differential effect on MACE or other outcomes between lipophilic and hydrophilic statins in patients with ACS undergoing PCI.